The FDA granted a supplemental approval for Rinvoq (upadacitinib) on April 28, 2025. This approval, designated as a supplemental new drug application (sNDA 211675 S-25), specifically addresses efficacy, indicating an expansion of the drug's approved therapeutic uses.
Background
Upadacitinib, known by its brand name Rinvoq, is developed by AbbVie. Supplemental applications are a standard regulatory mechanism for drug manufacturers to propose changes to an already approved drug. These changes often relate to new indications, modified dosing regimens, or expanded patient populations, all based on new clinical data demonstrating efficacy. This process allows for the continuous evolution of a drug's label as more research becomes available.
What this means
This supplemental approval for Rinvoq (upadacitinib) signifies that the FDA has thoroughly reviewed and accepted new data supporting the drug's efficacy in an additional context. While the specific details of the expanded indication or patient population are not explicitly provided in the approval summary, such regulatory actions typically broaden the scope of a drug's use. This means Rinvoq can now be prescribed for new conditions or to different groups of patients where its effectiveness has been scientifically demonstrated, thereby increasing its overall utility for healthcare providers and offering new treatment options for patients.
Source
The information regarding this supplemental approval was obtained directly from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application NDA 211675 S-25 for Rinvoq (upadacitinib), sponsored by AbbVie, was officially posted on April 28, 2025, on accessdata.fda.gov.